Visita y observación en la vereda

Markets remain Iran, Iraq and the Republic of South Africa.

Krka is the leading producer of medicines in Region West Europe, with esomeprazole, clopidogrel, perindopril, galantamine, gliclazide, ropinirole, duloxetine, pregabalin, aripiprazole and pramipexole.

Region West Europe

Overall sales in Region West Europe totalled €306.1 million, 22% more than in 2014. We increased sales of prescription pharmaceuticals through third partners by 4% after a decline of several years, especially owing to very successful sales in Great Britain. We continue to increase sales through subsidiaries. Sales of products marketed under our own brands rose by over 35%, and their share rose to more than 60% of overall sales in the region.

Prescription pharmaceuticals, in particular esomeprazole, duloxetine, pregabalin, pantoprazole, clopidogrel, and candesartan, were the leading products in the region. Through associated companies in particular, Krka successfully launched several medicines after product patents had expired, including

duloxetine, pregabalin and aripiprazole, which we launched as the first generic company in most Western European markets. Sales of animal health products increased by over a quarter compared to 2014. The best-selling product was milbemycin in combination with praziquantel. Total sales of non-prescription products rose by 11% compared to 2014. Germany and Portugal were the most successful markets in terms of sales.

Germany is our most important Western European market. It generated sales of €85.3 million, almost 27% more than the

year before. We generated over 90% of sales in the German market through our subsidiary TAD Pharma. We recorded an increase in sales primarily owing to healthy sales of several products for the treatment of cardiovascular diseases, medicines for the treatment of diseases of the alimentary tract and metabolism, and medicinal products for the treatment of the central nervous system. In the first quarter of 2015, we were the first generic producer to launch a medicinal product with duloxetine, under the brand Duloxalta, which was the leading product in terms of sales in 2015 in Germany. It was followed by Pregabador (pregabalin), Pantoprazol TAD (pantoprazol), Aripipan (aripiprazol) and Candecor/Candecor comp (candesartan and the combination with hydrochlorothiazide). The second market in the region in terms of sales was Spain, with €43.7 million. Sales through our subsidiary Krka Farmaceutica increased by over 15%, now accounting for over 80% of total sales in Spain. In Scandinavian countries, sales in 2015 reached nearly €40 million, an increase of nearly fifty percent compared to 2014. This was mainly the result of a successful launch of modern products for the treatment of the central nervous system with pregabalin, aripiprazole and duloxetine. Our sales were most substantial in Sweden, followed by Denmark and Norway. In France, sales amounted to a little less than €33 million, which is a 1% increase on the year before, especially due to good sales of esomeprazole through third partners. In Great Britain, we sold nearly €30 million worth of products, which is almost 50% more than in 2014. This was due to successful sales of medicines containing aripiprazole, duloxetine, pramipexole in the pharmaceutical form with prolonged release and pioglitazone. Total sales in

Italy increased by over 30%, reaching €21.1 million, especially because of doubled sales through our subsidiary Krka

Farmaceutici Milano. In Portugal, our sales totalled €20.6 million, or 5% more than the year before. Krka Farmacêutica has been one of the Portuguese pharmaceutical market leaders in terms of relative and absolute sales growth rates for some time. In the Benelux countries, where we sold €13.2 million worth of products, sales were down €1 million due to lower sales through third partners. In other European countries, we sold €8.2 million worth of products through third partners, which is an increase of 9% over 2014.

In Ireland, sales in 2014 through the subsidiary Krka Pharma Dublin increased by over two and a half times. Due to this increase, sales amounted to €6.2 million, accounting for an increase of 40%. Sales in Austria rose by 36%, totalling €6 million. The subsidiary Krka Pharma, Wien increased sales compared to 2014 by more than 50%.

Region Overseas Markets

In Region Overseas Markets, sales reached €31.7 million, 24% growth compared to 2014. Almost 90% was contributed by prescription pharmaceuticals, which we sell under our own brand names in most markets in the region.

In the markets of the Middle East, we sold €15.6 million worth of products, reaching 21% growth compared to 2014. Krka's biggest individual market in this region is Iran, with 25% sales growth compared to 2014. The best-selling products were Asentra (sertraline), Nolpaza (pantoprazol),

68

The increase in sales was highest in Vietnam, which became the fourth largest market in the region.

Letizen (cetirizine), Fromilid (clarithromycin), Ultop (omeprazole), Zyllt (clopidogrel) and Yasnal (donepezil). In Iraq, we maintained sales, especially in the north (Kurdistan), and increased sales by 47% compared to 2014. In Lebanon, most product launches were postponed to 2016 due to long procedures for marketing authorisations.

In the markets of the Far East and Africa, we recorded overall sales of €15.4 million and achieved a 28% increase over the year before. The Republic of South Africa remained the most important individual market, where we achieved 14% sales growth, with strong sales of especially the following medicinal products with the active substances: lansoprazole, enalapril, amlodipine and carvedilol. Through high sales growth, which was the result of expanding our product range,

Vietnam has become Krka's largest market in the Far East, followed by Malaysia, China and Singapore.

In the Americas, we increased sales by 16% compared to the year before. The markets of

Central America saw the highest growth. The leading products in terms of sales were Valsacor (valsartan), Emanera

69